Company results surpass expectations.Biacore Biacore is a life science products company, based in Sweden specializing in measuring protein-protein interaction and binding affinity. The technology is based on surface plasmon resonance (SPR), an optical phenomenon that enables detection of unlabeled interactants in real time. reported a 1.4% decline in fourth quarter sales to SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. 158.6 million ($22.8 million = SEK 6.95 = $1) from SEK 160.8 million ($21.2 million = SEK 7.58 = $1), or a 7.5% increase in reported dollars. Year-end year-end also year·end n. The end of a year. adj. Occurring or done at the end of the year: a year-end audit. Noun 1. 2004 sales slipped 3.8% to SEK 495.8 million ($67.5 million = SEK 7.34 = $1) from SEK 515.5 million ($63.8 million = SEK 8.08 = $1), or a 5.8% increase in reported dollars. The company benefited from European European emanating from or pertaining to Europe. European bat lyssavirus see lyssavirus. European beech tree fagussylvaticus. European blastomycosis see cryptococcosis. and Asian-Pacific fourth quarter sales growth of 18% and 15%, respectively, which was offset by a 24% decline in sales to the Americas A·mer·i·cas , the See America. . For the year, sales to the Americas declined 19% to account for 38% of total sales, European sales climbed 36% to represent 37% of sales and Asian-Pacific revenue dropped 17%. Excluding negative currency effects, sales to the Americas declined 4% due to weak pharmaceutical and academic sales, which were partially offset by increased biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. sales. European sales benefited from improved sales processes A sales process is a systematic approach for performing product or service sales. The reasons for having a sales process include seller and buyer risk management, achieving standardized customer interaction in sales and scalable revenue generation. as well as increased funding for academic and industrial customers. The lack of funding in Japan for academic research led to the year-end decline of Asia-Pacific The term Asia-Pacific generally applies to littoral East Asia, Southeast Asia and Australasia near the Pacific Ocean, plus the states in the ocean itself (Oceania). sales, but appears to have improved during the fourth quarter. The company reported a 5.9% decline in fourth quarter adjusted operating income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. to SEK 50.8 million ($7.3 million) and a 13.4% decline in year-end adjusted operating income to SEK 92.1 million ($12.6 million). Biacore expects increased sales in 2005 and a return to historical levels of profitability. Bio-Rad Laboratories reported fourth quarter sales growth of 19.3% to $307.9 million and full-year revenue growth of 11.3% to $1,090.0 million. Excluding currency effects, fourth quarter sales improved 14.1% and year-end revenues gained 5.5%, largely due to the acquisition of MJ GeneWorks. Adjusted operating income for the quarter dropped 21.9% to $25.6 million and 16.2% for the year to $123.5 million. Fourth quarter Life Science sales grew 21.6% to $148.5 million, or 16.4% excluding currency effects. Life Science sales growth was primarily derived from the acquisition of MJ GeneWorks as well as from increased sales of protein expression, electrophoresis electrophoresis (ĭlĕk'trōfərē`sĭs): see colloid. electrophoresis Movement of electrically charged particles in a fluid under the influence of an electric field. , consumables and multiplex See multiplexing. array product systems, which was slightly offset by price erosion in the BSE See Bombay Stock Exchange. BSE See Boston Stock Exchange (BSE). market. Life Science fourth quarter operating profit Operating profit (or loss) Revenue from a firm's regular activities less costs and expenses and before income deductions. operating profit See operating income. slipped 7.1% due to the decline in BSE sales and softness in Japan because of continued weak academic funding. Full-year Life Science sales improved 10.6% to $504.7 million, or 4.8% on a currency-neutral basis. Bio-Rad forecasts mid to high single-digit revenue growth for the company in 2005, with growth higher during the first half due to comparative reasons as MJ GeneWorks was acquired in August. Caliper caliper Instrument that consists of two adjustable legs or jaws for measuring the dimensions of material parts. Spring calipers have an adjusting screw and nut; firm-joint calipers use friction at the joint to hold the legs unmoving. Life Sciences' fourth quarter revenue grew 12.6% to $24.1 million. The company cut its operating loss operating loss The excess of operating expenses over revenue. As with operating income, operating losses exclude revenues and expenses from operations that are not considered a regular part of the business. Also called deficit. Compare operating income. by two-thirds to $2.6 million. Product revenue jumped 33% to $18.1 million, service revenue improved 3.8% to $3.4 million, while license fees and contract revenue tumbled 41.7% to $2.7 million. The company met the low end of its year-end revenue forecast as sales increased 62.1% to $80.1 million. The company cut its year-end operating loss in half to $18.9 million, The company anticipates first quarter revenue of around $18 million and year-end revenue between $87 million and $92 million. Caliper has also set a goal of break-even cash flow by the fourth quarter of 2005. Illumina reported a 37.6% jump in fourth quarter revenue to $14.8 million. Fourth quarter product revenue gained 33% to $10.4 million, service revenue nearly doubled to $4.0 million and research revenue dropped 64% to $0.3 million. The company improved its adjusted operating loss by $3 million to a loss of just $0.1 million. Year-end sales climbed 80% to $50.6 million and operating income improved over 60% to a loss of $8.9 million. The company was able to book 22 service contracts during the fourth quarter and 52 for the year, well above its goal. Illumina also surpassed its goal for BeadStations as well, shipping 13 stations in the quarter and 42 for the year. The company's installed base now stands at 49. The company experienced strong sales across all major geographic regions, with the US accounting for approximately 50% of total sales. Illumina anticipates 2005 revenue growth between 48% and 62% to $75-$82 million. System sales System sales is a business term used in the franchising industry. Franchisors provide supplies, marketing and administration services to franchisees in return for a part of the franchisees' revenues. Some franchisors also operate some outlets directly. are expected to double, driven by continued strength in consumables sales. Illumina forecasts the fourth quarter of 2005 to be its first profitable quarter and 2006 to be its first profitable year. First quarter 2005 revenue is projected to be $13-$15 million. The company plans to increase its focus on clinical research and molecular diagnostics (1) Software routines that test hardware components (memory, keyboard, disks, etc.). Diagnostics are often stored in ROM chips and activated on startup. (2) Error messages in a programmer's source code that refer to statements or syntax that the compiler or assembler through partnerships and collaborations. Invitrogen announced a 26.2% jump in fourth quarter revenue to $262.2 million, with operating income climbing 62% to $66.5 million, excluding one-time charges. Fourth quarter BioDiscovery sales improved 7.2% to $149.0 million, while BioProduction revenue leaped 64.5% to $113.2 million. Excluding acquisition and currency effects, the BioDiscovery reported 3% growth and BioProduction sales grew 13%. Sales to the Americas improved 28% to account for 55% of sales, European sales jumped 34% to represent 30% of sales and Asian-Pacific sales grew 39%. Full-year revenue gained 31.6% to $1,023.9 million, with operating profit improving 41.9% to $243.4 million. For the year, BioDiscovery sales gained 18.2% to $591.4 million and Bioproduction revenue climbed 56%. On an organic basis, BioDiscovery and Bioproduction grew 2% and 11%, respectively. BioDiscovery reported a 40% increase in year-end operating income to $156.2 million. Bioproduction year-end operating profit climbed 40% as well to $106.2 million. Invitrogen forecasts 2005 revenue of $1,164-$1,184 million. Mettler-Toledo's fourth quarter and year-end revenues improved 7.7% each to $399.2 million and $1,404.5 million, respectively. In the quarter, sales grew 3% on an organic base and currency effects added 5%. Adjusted fourth quarter operating income gained 9.1% to $59.0 million. Adjusted year-end operating profit climbed 10.8% to $179.4 million. Sales of laboratory-related products improved 2% during the fourth quarter and 4% for the year due to improved market conditions and new products. Adjusted for the exit of an electronic components business related to one customer, lab sales grew 4% for the quarter and 6% for the year. Process analytics and drug discovery products reported double-digit growth during the quarter, while balance sales were virtually flat due to tough year-over-year comparison. Mettler-Toledo forecasts 2005 revenue growth for the total company of 3%-5%, with an additional 1%-2% growth from currency effects. Sales of balances are estimated to grow 2%-4%, process analytics should exhibit high single-digit growth and AutoChem products are expected to show good growth as well. |
|
|||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion